Compass Therapeutics Investor Presentation Deck

Stitch MabsTM Platform was Utilized to Identify CTX-8371 Unexpected synergistic activity of PD-1/PD-L1 combination in bispecific Stitchmab format IFNg (pg/ml) 3000- 2000- 1000- T1 X - Y VS Pembro/Atezo Stitchmab Nivo/Atezo Stitchmab COMPASS THERAPEUTICS Cocktail Pembro + Atezo T2 0 10 pM 0.1 PM Nivo + Atezo Cocktail Mixed lymphocyte reaction (MLR) assay Pembro Common Light Chain bispecifics were generated to test therapeutic hypothesis PD-1 PD-L1 CTX-8371 Our PD-1xPD-L1 bispecifics observed to outperform PD-1 blockers in T-cell activation assay 1400¬ 1200- 1000- 800- 600- 200 0.0001 Plate 1 0.001 0.01 0.1 1 Ab concentration (nM) 10 PD-1xPD-L1 v1 PD-1xPD-L1 v2 Keytruda Nivolumab Isotype Control No Ab Control 34

View entire presentation